Optimizing Cardiovascular Risk in PLWH: Real-World Efficacy and Lipid Kinetics of Fixed-Dose Combination Rosuvastatin Ezetimibe.
- 1Clinic of Infectious Diseases, Department of Medicine and Aging Science, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.
- 2Infectious Disease Clinic, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy.
- 3Institute of Internal Medicine, Department of Medicine and Aging Science, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.
Abstract
Background
People living with HIV (PLWH) have increased cardiovascular disease risk, and dyslipidemia remains a major modifiable factor. Achieving recommended low-density lipoprotein cholesterol (LDL-C) targets can be challenging.Objective
To evaluate the real-world effectiveness and safety of fixed-dose low-dose rosuvastatin/ezetimibe in virologically stable PLWH and to describe lipid-lowering kinetics in comparison with an HIV-negative control cohort.Methods
This retrospective single-center study included 32 PLWH and 43 HIV-negative outpatients receiving rosuvastatin 5 mg plus ezetimibe 10 mg daily. Lipid parameters, cardiovascular risk scores, and safety markers were assessed at baseline, 3 months, and 6 months.Results
In PLWH, LDL-C decreased from 170.7 ± 35.1 to 87.8 ± 24.6 mg/dL at 6 months, corresponding to a mean reduction of 46.7% (p < 0.001). Total cholesterol and non-HDL cholesterol also decreased significantly (p < 0.001 for both), while triglycerides decreased significantly at month 6 (p = 0.016). Overall, 53.1% of PLWH reached guideline-recommended LDL-C targets. Both the 5-year and 10-year D:A:D scores decreased significantly during follow-up (p < 0.001 for both). The exploratory comparison suggested a more rapid early lipid response among HIV-negative controls, with most of the reduction occurring by month 3. No treatment-limiting adverse events or viro-immunological deterioration occurred.Conclusions
Low-dose rosuvastatin combined with ezetimibe was associated with substantial improvement in atherogenic lipid parameters in virologically stable PLWH, while the exploratory finding of an earlier response among HIV-negative controls may support further investigation of treatment-response kinetics.
Related
- Effect of rosuvastatin and ezetimibe therapy on LDL-cholesterol reduction and non-invasive arterial injury markers in children with heterozygous familial hypercholesterolemia: a prospective, open-label, randomized study
- Effectiveness and safety of atorvastatin/ ezetimibe fixed-dose combination in hypercholesterolemia: a systematic review and network meta-analysis
- Optimizing Indocyanine Green Fluorescence Cholangiography in Laparoscopic Cholecystectomy: A Systematic Review of Randomized Controlled Trials on Dose, Timing, Route, Efficacy, and Safety
- Evaluation of the Efficacy and Safety of Combination Therapy of Vamha and Myrha in the Management of PMOS: An Open-Label, Randomized, Multicentre, Comparative, Prospective Clinical Study
- Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol
BibTeX
@article{falasca2026optimizing,
title = {{Optimizing Cardiovascular Risk in PLWH: Real-World Efficacy and Lipid Kinetics of Fixed-Dose Combination Rosuvastatin Ezetimibe.}},
author = {Katia Falasca and Claudio Ucciferri and Damiano D'Ardes and Raffaele Ferri and Livia Moffa and Francesca Chiappini and Riccardo Mattia Ricciardi and Francesco Cipollone and Jacopo Vecchiet},
journal = {Infectious disease reports},
year = {2026},
month = oct,
doi = {10.3390/idr18050119},
url = {https://europepmc.org/article/MED/42930510},
note = {CC BY},
}
RIS
TY - JOUR
TI - Optimizing Cardiovascular Risk in PLWH: Real-World Efficacy and Lipid Kinetics of Fixed-Dose Combination Rosuvastatin Ezetimibe.
AU - Katia Falasca
AU - Claudio Ucciferri
AU - Damiano D'Ardes
AU - Raffaele Ferri
AU - Livia Moffa
AU - Francesca Chiappini
AU - Riccardo Mattia Ricciardi
AU - Francesco Cipollone
AU - Jacopo Vecchiet
PY - 2026
DA - 2026/10/16
JO - Infectious disease reports
DO - 10.3390/idr18050119
UR - https://europepmc.org/article/MED/42930510
AB - Background People living with HIV (PLWH) have increased cardiovascular disease risk, and dyslipidemia remains a major modifiable factor. Achieving recommended low-density lipoprotein cholesterol (LDL-C) targets can be challenging.Objective To evaluate the real-world effectiveness and safety of fixed-dose low-dose rosuvastatin/ezetimibe in virologically stable PLWH and to describe lipid-lowering kinetics in comparison with an HIV-negative control cohort.Methods This retrospective single-center study included 32 PLWH and 43 HIV-negative outpatients receiving rosuvastatin 5 mg plus ezetimibe 10 mg daily. Lipid parameters, cardiovascular risk scores, and safety markers were assessed at baseline, 3 months, and 6 months.Results In PLWH, LDL-C decreased from 170.7 ± 35.1 to 87.8 ± 24.6 mg/dL at 6 months, corresponding to a mean reduction of 46.7% (p < 0.001). Total cholesterol and non-HDL cholesterol also decreased significantly (p < 0.001 for both), while triglycerides decreased significantly at month 6 (p = 0.016). Overall, 53.1% of PLWH reached guideline-recommended LDL-C targets. Both the 5-year and 10-year D:A:D scores decreased significantly during follow-up (p < 0.001 for both). The exploratory comparison suggested a more rapid early lipid response among HIV-negative controls, with most of the reduction occurring by month 3. No treatment-limiting adverse events or viro-immunological deterioration occurred.Conclusions Low-dose rosuvastatin combined with ezetimibe was associated with substantial improvement in atherogenic lipid parameters in virologically stable PLWH, while the exploratory finding of an earlier response among HIV-negative controls may support further investigation of treatment-response kinetics.
SN - 2036-7430
SN - 2036-7449
ER -